CClinicalTrials.gg
CompletedNCT03274960PretermbirthUpdated May 11, 2023

Screening and Treating Asymptomatic Bacteriuria Every Trimester and Preterm Birth

An interventional study of Griess, in Preterm Birth and Asymptomatic Bacteriuria in Pregnancy, sponsored by University of Zimbabwe. Completed at 1 site in Zimbabwe. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by University of Zimbabwe · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
480
Allocation
Randomized
Sex
Female
01

Study summary

This study is evaluating whether screening of a pregnant woman for asymptomatic bacteriuria in each trimester for early detection and treatment of bacteriuria will reduce the incidence of preterm birth in Harare.

Read the detailed description

Asymptomatic bacteriuria is common in pregnancy. If the disease is not detected early in pregnancy and treated it often progresses to an acute symptomatic disease, pyelonephritis which is associated with adverse pregnancy outcomes including preterm birth.

It is recommended that every woman be screened for asymptomatic bacteriuria by urine culture test at initial antenatal care visit so that the disease is if identified is treated early to prevent preventable complications of the disease in pregnancy. Culture test is expensive and therefore unavailable at several primary care settings especially in low resource settings where majority of pregnant women register and visit for antenatal care. In Zimbabwe antenatal care at primary care clinics is not including screening for asymptomatic bacteriuria. Majority who present with symptoms are empirically treated.

In this study the Griess nitrite test, an effective inexpensive screening test for asymptomatic bacteriuria is used. the test detects nitrite in urine which is associated with presence of nitrate reducing uropathogens, commonly the gram negative bacteria. All the positive samples will then be further tested by culture for bacteria identification, quantification and antibiotic sensitivity. A Randomized controlled trial research design is being used. participants are randomly allocated to intervention group or control group. Urine samples will be collected and tested 3 times for each recruited participant in the intervention arm. treatment will be initiated for positive result according to sensitivity test. Control group will only be subjected to routine existing antenatal care.

Participants will be recruited before 22 weeks gestation and followed on for second contact by 28 weeks and third contact by 36 weeks. Follow up will be stopped on delivery for noting gestation at delivery, whether preterm or term.

02

Conditions studied

  • Preterm Birth
  • Asymptomatic Bacteriuria in Pregnancy

Keywords

  • asymptomati bacteriuria, Griess nitrite test, preterm birth
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Pregnant women registering at study site.
  • Woman is able to identify her date of last menstrual period.
  • Gestation of pregnancy is between 6 and 22 weeks.
  • Woman is asymptomatic for bacteriuria
  • Woman voluntarily signs the consent form

Exclusion criteria

Exclusion Criteria:

  • Pregnant woman ill and unwell
  • Pregnant woman unwilling to sign consent form
  • Woman who had antibiotic treatment 2 weeks before recruitment
  • Woman on long term antibiotic treatment
  • Woman who fails to identify date of last menstrual period
  • Woman symptomatic for urinary tract infection
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
480 participants (actual)

Study arms

  • Experimental
    Griess, Culture and antibiotic

    Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.

    Combination Product: Griess,

  • No intervention
    No Griess, culture, treatment

    No Griess reagents added in urine sample, no culture test with blood agar and no treatment with antibiotic for every positive results every trimester

Interventions

  • Combination productGriess,

    Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.

    Also known as: Culture, Treatment

05

What researchers measure

Primary outcomes

  1. Preterm birth

    Preterm birth will be delivery of a baby before 37 complete weeks of gestation from the first date of last menstrual period. It will be sub-categorized as extremely preterm (\<28 weeks), very preterm (28 to \<32 weeks) and moderate to late preterm (32 to \<37 weeks).

    Time frame: Preterm birth will be calculated as gestation at birth of baby using date of birth and the first date of last menstrual period.

Secondary outcomes

  1. symptomatic bacteriuria

    Noted from history of urinary tract symptoms which include pain on micturition, fever, blood in urine, increased urine frequency, foul smelling urine and cloudy urine.

    Time frame: The symptoms will be noted at interviews at follow up after every 6 to 8 weeks from previous contact.

  2. Isolated uropathogen

    All isolated bacterial species from urine sample identified from culture test. These are bacteria identified to be responsible for asymptomatic bacteriuria.

    Time frame: These will be available at recruitment by 22 weeks, between 22 and 28 weeks at second screening and at 28 to 36 weeks at the third screening.

  3. Antibiotic sensitivity

    from urine culture results identified antibiotics sensitive for treatment of isolated bacteria will be noted.

    Time frame: These will be available at recruitment by 22 weeks, between 22 and 28 weeks at second screening and at 28 to 36 weeks at the third screening

  4. Gestation at birth

    Gestation is the calculated total number of weeks from first date of last menstrual period to the date of delivery.

    Time frame: Gestation will be calculated at delivery of baby.

06

Study locations

1 site
  • University of Zimbabwe
    Harare, Metropolitan +263, Zimbabwe
07

References and documents

Individual participant data

Plan to share: Yes — plan to share individual participant information will include sharing culture test results on antibiotic sensitivity for those with positive urine culture results. the in formation shared is intended to assist with effective decision making on selection of the best antibiotic to use to treat asymptomatic bacteriuria.

Supporting information: Study protocol, Csr

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03274960
Lead sponsor
University of Zimbabwe
Responsible party
Judith Rukweza, DPhil Student (Mrs, University of Zimbabwe) — Principal investigator
First posted
Sep 7, 2017
Start date
Feb 23, 2017
Primary completion
Jan 30, 2020
Completion
Dec 30, 2020
Last update
May 11, 2023

Study contacts

Muchabaiwa F Gidiri, MD
study director · Senior Lecturer, Chairperson Obstetrics and Gynecology Department, University of Zimbabwe
Pasipanodya Nziramasamga, PHD
study director · Senior Lecturer, Medical Microbiology Department, University of Zimbabwe
Babil Stray- Pedersen, Professor
study director · Doctor, Medisin Department, Oslo University
Clara Haruzivishe, PHD
study chair · Senior lecturer, Department of Nursing Science, University of Zimbabwe

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion